RVL Pharmaceuticals plc

-0.01 (-5.75%)
7:41:01 PM EDT: $0.10 0.00 (3.40%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)10.50M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$7.24 Million
Adjusted EPS-$0.09
See more estimates
10-Day MA$0.11
50-Day MA$0.27
200-Day MA$0.85
See more pivots

RVL Pharmaceuticals plc Stock, NASDAQ:RVLP

400 Crossing Boulevard, Bridgewater, New Jersey 08807
United States of America
Phone: +1.908.809.1300
Number of Employees: 125


RVL Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs. The company was founded in 1986 and is headquartered in Bridgewater, NJ.